BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 12782577)

  • 21. Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.
    Newton HB
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):105-28. PubMed ID: 14748662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
    Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
    Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
    Haas-Kogan D; Shalev N; Wong M; Mills G; Yount G; Stokoe D
    Curr Biol; 1998 Oct; 8(21):1195-8. PubMed ID: 9799739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    DeGraffenried LA; Fulcher L; Friedrichs WE; Grünwald V; Ray RB; Hidalgo M
    Ann Oncol; 2004 Oct; 15(10):1510-6. PubMed ID: 15367412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3beta signaling and leads to an increased transit time through the G1 phase of the cell cycle.
    Horn S; Endl E; Fehse B; Weck MM; Mayr GW; Jücker M
    Leukemia; 2004 Nov; 18(11):1839-49. PubMed ID: 15457186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
    Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI
    Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
    Sekulić A; Hudson CC; Homme JL; Yin P; Otterness DM; Karnitz LM; Abraham RT
    Cancer Res; 2000 Jul; 60(13):3504-13. PubMed ID: 10910062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
    Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
    Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of complex protein kinase B signalling pathways in human prostate cancer samples.
    Jendrossek V; Henkel M; Hennenlotter J; Vogel U; Ganswindt U; Müller I; Handrick R; Anastasiadis AG; Kuczyk M; Stenzl A; Belka C
    BJU Int; 2008 Aug; 102(3):371-82. PubMed ID: 18476967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
    Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
    Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of tumor suppressor p53 decreases PTEN expression and enhances signaling pathways leading to activation of activator protein 1 and nuclear factor kappaB induced by UV radiation.
    Wang J; Ouyang W; Li J; Wei L; Ma Q; Zhang Z; Tong Q; He J; Huang C
    Cancer Res; 2005 Aug; 65(15):6601-11. PubMed ID: 16061640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
    Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
    Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
    Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
    Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of FOXO3a by brain-derived neurotrophic factor in differentiated human SH-SY5Y neuroblastoma cells.
    Zhu W; Bijur GN; Styles NA; Li X
    Brain Res Mol Brain Res; 2004 Jul; 126(1):45-56. PubMed ID: 15207915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling.
    Zhang B; Cao H; Rao GN
    Cancer Res; 2005 Aug; 65(16):7283-91. PubMed ID: 16103079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression.
    Hutchinson J; Jin J; Cardiff RD; Woodgett JR; Muller WJ
    Mol Cell Biol; 2001 Mar; 21(6):2203-12. PubMed ID: 11238953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
    Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
    Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pten signaling in gliomas.
    Knobbe CB; Merlo A; Reifenberger G
    Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway.
    Zhang J; Choi Y; Mavromatis B; Lichtenstein A; Li W
    Oncogene; 2003 Sep; 22(40):6289-95. PubMed ID: 13679867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.